Caspofungin in the treatment of candidosis and aspergillosis (Q42162634)

17 October 2017

title

Caspofungin in the treatment of candidosis and aspergillosis (English)

1 reference

17 October 2017

0 references

1 reference

1

Johan Maertens

1 reference

17 October 2017

Marc Boogaerts

2

1 reference

17 October 2017

language of work or name

1 reference

1 June 2003

1 reference

17 October 2017

number of pages

8

1 reference

International Journal of Infectious Diseases

inferred from page(s)

published in

1 reference

17 October 2017

volume

7

1 reference

17 October 2017

issue

2

1 reference

17 October 2017

page(s)

94-101

1 reference

17 October 2017

cites work

Invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Aspergillosis case-fatality rate: systematic review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Trends in the postmortem epidemiology of invasive fungal infections at a university hospital

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Critical assessment of issues in the diagnosis of invasive aspergillosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Pulmonary aspergillosis: early diagnosis improves survival

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Early detection of aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Mortality and costs of acute renal failure associated with amphotericin B therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Lipid formulations of amphotericins: are you a lumper or a splitter?

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Antibiotics that inhibit fungal cell wall development

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Fungal cell wall inhibitors: emphasis on clinical aspects

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Lipopeptide inhibitors of fungal glucan synthase

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Comparison of caspofungin and amphotericin B for invasive candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

Progressive cutaneous hyalohyphomycosis due to Paecilomyces lilacinus: rapid response to treatment with caspofungin and itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990003-8

7 January 2021

10.1016/S1201-9712(03)90003-8

Identifiers

DOI

1 reference

17 October 2017

1 reference